Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biontech Se ADR (NQ: BNTX )

113.13 +4.90 (+4.53%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biontech Se ADR

< Previous 1 2 3 4 5 6 7 8 9
...
65 66 Next >
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024
From BioNTech SE
Via GlobeNewswire
Elon Musk Breaks Ranks With GOP By Praising Genetic Engineering Tech That Helped Fight COVID-19: 'Digital Medicine With Incredible Potential'
Elon Musk has come off as a flagbearer of the mRNA technology, which is seen holding out a lot of promise by scientists. 
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For BioNTech
Via Benzinga
BioNTech Se (BNTX) Q1 2024 Earnings Call Transcript
BNTX earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Assessing BioNTech: Insights From 11 Financial Analysts
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For BioNTech
Via Benzinga
BNTX Stock Earnings: BioNTech Misses EPS, Misses Revenue for Q1 2024
BNTX stock results show that BioNTech missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
What's Going With BioNTech Stock On Monday?
BioNTech reports Q1 loss, missing revenue expectations. Despite challenges, BioNTech aims for significant growth, fueled by innovative R&D and strong cash reserves. 
Via Benzinga
BioNTech Slides After Reporting Losses As Covid Vaccine Sales Take A Hit
BioNTech missed the Street's sales views and reported wider-than-expected losses. 
Via Investor's Business Daily
Exposures COVID-19
BioNTech Reports Downbeat Earnings, Joins Medical Properties Trust And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Wall Street Looks To Extend Rally Amid Caution Over Fed Speeches, More Earnings: Why This Analyst Thinks Bull Market Is Still 'Quite Young'
U.S. stocks are likely to extend their gains as major index futures are modestly higher on Monday. Strong earnings reports continue to support the market, with S&P 500 earnings expected to grow by 5%... 
Via Benzinga
Topics Economy
Exposures Interest Rates
BioNTech Announces First Quarter 2024 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
GSK Sees Strong Demand For Vaccines and Asthma Drugs, Raises Annual Outlook
Discover GSK's first-quarter performance, boasting a 10% Y/Y sales surge to £7.4 billion. Notable growth in Vaccines and Specialty Medicines, propelled by strong demand for Arexvy and Shingrix.... 
Via Benzinga
COVID-19 Patent Dispute Sorted: Acuitas Therapeutics and CureVac Reach Settlement In Patent Battle
Acuitas Therapeutics settles lawsuit with CureVac over COVID-19 vaccine patents. Legal disputes unfold among biotech giants Pfizer, BioNTech, and CureVac, as GSK joins the fray, alleging patent... 
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures COVID-19 Financial Intellectual Property
What's Going On With Pfizer Stock On Thursday?
GSK initiates legal proceedings against Pfizer and BioNTech over alleged COVID-19 vaccine patent infringement, intensifying high-stakes legal battles in the U.S. 
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Will Earnings Cheer Continue This Week? All Eyes On Disney, Palantir, Robinhood While Reddit Gears Up For Debut Quarterly Report
According to FactSet, a financial data analytics firm, 80% of S&P 500 companies have reported earnings so far. 
Via Benzinga
Topics Stocks
Exposures US Equities
Moderna Faces Pfizer, BioNTech in London Patent Battle over Covid-19 Vaccines In Legal Showdown
Moderna challenges Pfizer and BioNTech in a London patent trial over mRNA vaccine patents. The outcome may reshape the pharmaceutical landscape, impacting future innovations and revenue streams. 
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
From BioNTech SE
Via GlobeNewswire
Bill Gates Called For A 'Universal Flu Vaccine,' Now The CDC Director Says The Organization Is 'Activated' After Issuing Bird Flu Alert
Via Benzinga
Election Year Encore: Can 2020’s Top 7 Stock Winners Repeat Their Performance in 2024?
These seven companies were the top 2020 stocks. After their glory years have faded, they are looking to turn their fortunes around. 
Via InvestorPlace
Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer
From BioNTech SE
Via GlobeNewswire
CureVac, GS Partner Release Data On Influenza Vaccine Study
CureVac reveals Phase 2 interim data for its seasonal influenza vaccine in collaboration with GSK. Results show broad antigen coverage with acceptable safety. Positive findings against influenza A... 
Via Benzinga
The 3 Best Bargain Stocks to Buy in Q2 2024
For those who don’t want to chase what everyone else is acquiring, these are intriguing ideas for best bargain stocks to buy. 
Via InvestorPlace
3 Biotech Stocks to Buy for the Next Bull Run: March 2024
These biotech stocks to buy are well positioned for growth, and will generate solid returns for investors in the next bull run. 
Via InvestorPlace
BioNTech Se (BNTX) Q4 2023 Earnings Call Transcript
BNTX earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Why Lifecore Biomedical Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Lifecore Biomedical, Inc. (NASDAQ: LFCR) fell sharply during Wednesday’s session after the company announced it concluded its strategic evaluation process, announced management succession and... 
Via Benzinga
BioNTech Touts Its Oncology Shift After Reporting Disappointing Fourth Quarter Financials
BioNTech SE (NASDAQ: BNTX) is way past its glorious Covid-19 days, when it thrived with Pfizer Inc (NYSE: PFE) for saving the world from the pandemic with their jointly developed vaccine. 
Via Benzinga
Exposures COVID-19
Stocks Quietly Higher As Central Bank Wraps Up Meeting
Stocks are cautiously higher ahead of the conclusion of the central bank's policy meeting. 
Via Talk Markets
Topics Economy
Exposures Interest Rates
BNTX Stock Earnings: BioNTech Misses EPS, Misses Revenue for Q4 2023
BNTX stock results show that BioNTech missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
BioNTech Tumbles As Fourth-Quarter Sales Dive 65% And Miss Forecasts
BioNTech also reported plummeting earnings that missed forecasts and issued light 2024 guidance. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
65 66 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.